Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type.
OBJECTIVE
To test the association between hospital type and performance of candidate quality measures for treatment of muscle-invasive bladder cancer (MIBC) using a large national tumour registry. Proposed quality measures include receipt of neoadjuvant chemotherapy, timely treatment, adequate lymph node dissection, and continent urinary diversion.


METHODS
Using the National Cancer Database, patients with stage ≥II urothelial carcinoma treated with radical cystectomy (RC) from 2003 to 2010 were identified. Hospitals were grouped by type and annual RC volume: community, comprehensive low volume (CLV), comprehensive high volume (CHV), academic low volume (ALV), and academic high volume (AHV) groups. Logistic regression models were used to test the association between hospital group and performance of quality measures, adjusting for year, demographic, and clinical/pathological characteristics; generalised estimating equations were fitted to the models to adjust for clustering at the hospital level.


RESULTS
In all, 23 279 patients underwent RC at community (12.4%), comprehensive (CLV 38%, CHV 5%), and academic (ALV 17%, AHV 28%) hospitals. While only 0.8% (175) of patients met all four quality criteria, 61% of patients treated at AHV hospitals met two or more quality metric indicators compared with ALV (45%), CHV (44%), CLV (38%), and community (37%) hospitals (P < 0.001). After adjustment, patients were more likely to receive two or more quality measures when treated at AHV (odds ratio [OR] 2.4, confidence interval [CI] 2.0-2.9), ALV (OR 1.3, CI 1.1-1.6), and CHV (OR 1.3, CI 1.03-1.7) hospitals compared with community hospitals.


CONCLUSIONS
Patients undergoing RC at AHV hospitals were more likely to meet quality criteria. However, performance remains low across hospital types, highlighting the opportunity to improve quality of care for MIBC.
Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Anthony T
AT
Corcoran
Elizabeth
E
Handorf
Daniel
D
Canter
Jeffrey J
JJ
Tomaszewski
Justin E
JE
Bekelman
Simon P
SP
Kim
Robert G
RG
Uzzo
Alexander
A
Kutikov
Marc C
MC
Smaldone
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015653:Cystectomy / Q000592:standards; D005260:Female; D006276:Health Facility Size / Q000706:statistics & numerical data; D006761:Hospitals / Q000592:standards*; D006801:Humans; D008197:Lymph Node Excision / Q000592:standards; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D020360:Neoadjuvant Therapy / Q000592:standards; D009361:Neoplasm Invasiveness; D011379:Prognosis; D058996:Quality Improvement; D011787:Quality of Health Care / Q000592:standards; D012042:Registries; D014481:United States / Q000453:epidemiology; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D014547:Urinary Diversion / Q000592:standards
D000970:Antineoplastic Agents
bladder cancer; hospital type; quality measures; radical cystectomy; surgical volume